title: [Expression of angiogenic factors and cell cycle regulation factors in human glioblastoma cell line SHG-44].
abstract: OBJECTIVE
  To investigate the biological features and immunophenotypes of human glioblastoma cell line SHG-44 after long term passage.
  
  
  METHODS
  Immunohistochemistry and in situ hybridization were used to study the proliferative activity, intermediate filament protein coexistence, expressions of oncoprotein, angiogenic factors and cell cycle regulation factors.
  
  
  RESULTS
  After 130 to 150 passages, SHG-44 cells were weakly positive for glial fibrillary acidic protein (GFAP), but strongly positive for vimentin. The labeling index of Ki-67 and PCNA were 83.5% +/- 10.2% and 70.0% +/- 18.7% respectively. Overexpression of p21 ras, c-erbB-2, epidermal growth factor (EGF) and EGF receptor were obtained. Basic fibroblast growth factor (bFGF), FGF receptor, vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) were also up-regulated in this cell line. p16, p53, cdk4 and cyclin D1 could be detected in the cells and their indices were 43.1% +/- 11.2%, 20.7% +/- 6.6%, 33.1% +/- 11.4% and 29.2% +/- 4.7% respectively.
  
  
  CONCLUSIONS
  Expressive abnormalities of these growth factors, their receptors and the above oncoproteins as well as disorders of cell cycle regulation contribute to the rapid growth and high degree of malignancy of this cell line.
authors.affiliation: Department of Pathology, Third Military Medical University, Chongqing 400038.
authors.forename: X
authors.initials: X
authors.lastname: Bian
authors.forename: Z
authors.initials: Z
authors.lastname: Chen
authors.forename: D
authors.initials: D
authors.lastname: Guo
authors.forename: L
authors.initials: L
authors.lastname: Du
authors.forename: R
authors.initials: R
authors.lastname: Xin
authors.forename: J
authors.initials: J
authors.lastname: Shi
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000235:genetics*; D018797:Cell Cycle Proteins / Q000096:biosynthesis*; D002455:Cell Division; D016228:Endothelial Growth Factors / Q000235:genetics; D004815:Epidermal Growth Factor / Q000032:analysis; D066246:ErbB Receptors / Q000032:analysis; D016222:Fibroblast Growth Factor 2 / Q000032:analysis; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics; D019394:Ki-67 Antigen / Q000032:analysis; D008222:Lymphokines / Q000235:genetics; D019001:Nitric Oxide Synthase / Q000032:analysis; D052247:Nitric Oxide Synthase Type II; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D043925:Angiogenesis Inducing Agents; D018797:Cell Cycle Proteins; D016228:Endothelial Growth Factors; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D016222:Fibroblast Growth Factor 2; D036341:Intercellular Signaling Peptides and Proteins; D019394:Ki-67 Antigen; D008222:Lymphokines; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C496319:NOS2 protein, human